2257 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Sirnaomics Ltd. is an international biopharmaceutical company that engages in developing and commercializing of RNAi technology and multiple therapeutics. Its lead clinical drug candidates include STP705 and STP707. It is capitalizing on its dual delivery platforms, which include Polypeptide nanoparticle (PNP) and GalAhead. The company was founded by Yang Lu in 2007 and is headquartered in Hong Kong.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
2257 has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company